tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of James Edwardes Jones, 10 are a HOLD (16.67%), 47 are a BUY (78.33%), 3 are a SELL (5%).
Analyst James Edwardes Jones, currently employed at RBC, carries an average stock price target met ratio of 33.9% that have a potential upside of 26.19% achieved within 57 days. Previously, James Edwardes Jones worked at OPPENHEIMER.
James Edwardes Jones’s has documented 109 price targets and ratings displayed on 18 stocks. The coverage is on Consumer Defensive, Healthcare sectors.
Most recent stock forecast was given on PLRX, Pliant Therapeutics at 10-Aug-2023.
Analyst best performing recommendations are on CYCC (CYCLACEL PHARMACEUTICALS).
The best stock recommendation documented was for CYCC (CYCLACEL PHARMACEUTICALS) at 3/7/2023. The price target of $10 was fulfilled within 3 days with a profit of $0.93 (8.51%) receiving and performance score of 28.36.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$41.84
$5.6 (15.45%)
11 months 2 days ago
(22-Jan-2024)
1/3 (33.33%)
$12.19 (41.11%)
570
Buy
$40.14
$3.9 (10.76%)
$50.92
1 years 17 days ago
(07-Dec-2023)
0/3 (0%)
$11.46 (39.96%)
Hold
$50
1 years 3 months 23 days ago
(01-Sep-2023)
0/1 (0%)
$17.03 (51.65%)
Hold
$37.53
$1.29 (3.56%)
$43.39
1 years 9 months 11 days ago
(13-Mar-2023)
1/5 (20%)
$3.75 (11.10%)
536
Buy
$44
$7.76 (21.41%)
$46.97
1 years 10 months 11 days ago
(13-Feb-2023)
0/4 (0%)
$9.27 (26.69%)
What Year was the first public recommendation made by James Edwardes Jones?
